EL7.AI
StocksMediumUpdated•Originally published 5 August 2026•Updated 8 August 2026•
1 min read

Eli Lilly Q2 Revenue Surges 48% on Weight-Loss Drug Demand; Raises Full-Year Guidance

Illustration of a man in a suit with Eli Lilly logo, financial data, and medical injection pens on an orange background.

Key Facts

1Eli Lilly reported a massive 48% increase in Q2 revenue to $23.0 billion, driven primarily by Mounjaro and Zepbound volumes.
2Eli Lilly raised its full-year financial guidance following strong second-quarter performance.
3Utz Brands reported a 1.4% increase in net sales to $371.8 million for the second quarter.

Reflecting the surging global demand for weight-loss treatments, Eli Lilly delivered a robust second-quarter 2026 financial performance. The company reported a massive 48% increase in revenue to $23.0 billion, a surge driven primarily by the sales volumes of its key products, Mounjaro and Zepbound. Following these strong results, management raised its full-year financial guidance, signaling continued confidence in its market leadership.

In the broader corporate landscape, results showed varying degrees of growth across sectors. Utz Brands reported a modest 1.4% increase in net sales to $371.8 million for the second quarter. Meanwhile, in the energy sector, Eos Energy tightened its full-year revenue outlook to a range of $300 million to $350 million, down from its previous upper limit of $400 million, according to market data and company filings.

Regarding stock performance, LLY stood at $1,115.68 at the close of August 4, 2026, having reached a day high of $1,135.83. Investors are now watching for sustained momentum following the Federal Reserve's decision on July 29 to hold interest rates at 3.75%, as the upcoming economic calendar shows few immediate domestic catalysts for the healthcare sector.